The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

caliperls.com

Founded Year

1995

Stage

Acq - P2P | Acquired

Total Raised

$37.09M

Valuation

$0000 

About Caliper Life Sciences

Caliper Life Sciences (NASDAQ: CALP) is a research tools company engaged in the sale of new and enabling products, services, and systems to academic, government and and biotech/pharmaceutical researchers worldwide. The company provides molecular solutions for preclinical imaging as well as in vitro research and diagnostics. Calipier's products and services, assembled from a portfolio of microfluidics, automation, liquid handling, and molecular imaging technologies, addresses various pre-clinical drug discovery and development bottlenecks. Its products and services include LabChip drug discovery, profiling and separations systems; IVIS noninvasive imaging systems, reagents and animal models; and automation and liquid handling systems. The company also offers contract research and transgenic animal services, drug discovery and development services, product support, and validation services.

Caliper Life Sciences Headquarter Location

68 Elm Street

Hopkinton, Massachusetts, 01748,

United States

508-435-9500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Caliper Life Sciences Patents

Caliper Life Sciences has filed 93 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • Microfluidics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/25/2018

2/1/2022

Molecular biology, Biotechnology, Laboratory equipment, Microfluidics, Polymerase chain reaction

Grant

Application Date

5/25/2018

Grant Date

2/1/2022

Title

Related Topics

Molecular biology, Biotechnology, Laboratory equipment, Microfluidics, Polymerase chain reaction

Status

Grant

Latest Caliper Life Sciences News

Life Science and Chemical Instrumentation Market Latest Industry Trends, Overview of Segments, Opportunities and Forecasts 2025 | Asia-Pacific is demonstrating high market growth

Dec 7, 2021

| Asia-Pacific is demonstrating high market growth Life Science and Chemical Instrumentation market players – Affymetrix, Inc., Agilent Technologies, Bio-Rad Laboratories, Life Technologies, Caliper Life Sciences, Abbott Laboratories, Siemens Healthcare Diagnostics, Hitachi High-technologies Corporation, Perkin Elmer, GE Healthcare and Roche Diagnostics, Inc., among others represent the global  Life Science and Chemical Instrumentation  market. The market study depicts an extensive analysis of all the players running in the Life Science and Chemical Instrumentation market report based on distribution channels, local network, innovative launches, industrial penetration, production methods, and revenue generation. Further, the market strategies and mergers & acquisitions associated with the players are enclosed in the Life Science and Chemical Instrumentation market report. Future Market Insights, in its latest business report, elaborates on the current situation of the global Life Science and Chemical Instrumentation market in terms of volume, value, production, and consumption. The report scrutinizes the market into various segments, end uses, regions, and players on the basis of demand patterns, and future prospects. Request For Report Sample Copy @  https://www.futuremarketinsights.com/reports/sample/rep-gb-395 Understanding the Impact of Covid-19 on Healthcare Industry With the pandemic plaguing maximum countries across the globe, healthcare industry is witnessing its fair share of ‘ups and downs’. The COVID-19 has placed an enormous strain on the healthcare sector’s workforce, facilities and infrastructure. Despite the endless pressure, healthcare sector is growing at a moderate pace due to the improvement in infrastructure and advancement in technology, healthcare sector is delivering a healthy performance. The FMI’s latest report on the Life Science and Chemical Instrumentation market gives a detailed analysis on the impact of COVID-19 with an incisive coverage on the innovative strategies adopted by the market players to survive the challenges due to pandemic. Critical Questions Answered in the Report What are ongoing trends that will shape market growth curve for global Life Science and Chemical Instrumentation market? What are the drivers and challenges affecting the Life Science and Chemical Instrumentation market demand? What are the recent technological advancement in the Life Science and Chemical Instrumentation market? What are key trends and opportunities that will prevail the revenue growth of Life Science and Chemical Instrumentation market players? How will evolving regulatory policies impact the market growth? What is the impact of Covid-19 on the Life Science and Chemical Instrumentation market? Request For Table Of Content @  https://www.futuremarketinsights.com/toc/rep-gb-395 Life Science and Chemical Instrumentation Market: Segmentation Based on the areas the technologies, the life science and chemical instruments market can be categorized as follows: Chromatography The Life Science and Chemical Instrumentation market research gets rid of the following queries: How the market for Life Science and Chemical Instrumentation is expected to shape in the coming ten years? What strategies are the Life Science and Chemical Instrumentation market vendors implementing to stay ahead of their rivals? Why are consumers shifting towards alternative Life Science and Chemical Instrumentation products? What innovative technologies are the Life Science and Chemical Instrumentation players using to get an edge over their rivals? What are the restraints affecting the growth of the global Life Science and Chemical Instrumentation market? Any Queries Regarding Report, Speak To Analyst @  https://www.futuremarketinsights.com/askus/rep-gb-395 Reasons to Buy the report We provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players. Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include. The report includes accurate analysis of the market and the current developing trends affecting the growth. FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. This ensures that the data collected is from highly reliable sources. Why Future Market Insights? Detailed insights of market segments and sub-segments for historical as well as forecast period A competitive analysis of prominent players and emerging players in the Life Science and Chemical Instrumentation market Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario Explore Wide-ranging Coverage of FMI’s Healthcare Market Insights Landscape About FMI Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Contact Jumeirah Lakes Towers, Dubai,

  • When was Caliper Life Sciences founded?

    Caliper Life Sciences was founded in 1995.

  • Where is Caliper Life Sciences's headquarters?

    Caliper Life Sciences's headquarters is located at 68 Elm Street, Hopkinton.

  • What is Caliper Life Sciences's latest funding round?

    Caliper Life Sciences's latest funding round is Acq - P2P.

  • How much did Caliper Life Sciences raise?

    Caliper Life Sciences raised a total of $37.09M.

  • Who are the investors of Caliper Life Sciences?

    Investors of Caliper Life Sciences include PerkinElmer, Finsbury Worldwide Pharmaceutical Trust plc, OrbiMed Advisors, Capital Group Companies, Galleon Management and 30 more.

  • Who are Caliper Life Sciences's competitors?

    Competitors of Caliper Life Sciences include BioDelivery Sciences International, KIYATEC, InvivoSciences, Sorrento Therapeutics, HTG Molecular Diagnostics, Sage Science, WaferGen Bio-systems, ZyGEM, Pieris, Life Technologies Corporation and 26 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

O
Ocimum Biosolutions

Ocimum Biosolutions is a life sciences RnD enabling company with three focus areas, BioIT (LIMS / Bioinformatics), BioMolecules, and BioResearch. Ocimum aims to deliver end to end genomic products and services out of three strategic locations worldwide, Indianapolis (United States), IJsselstien (The Netherlands), Hyderabad (India).

Biocom Logo
Biocom

Biocom works to drive public policy, build a network of industry leaders, create access to capital, introduce STEM education programs, and create value-driven purchasing programs.

S
SideroGen

SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.

Van Andel Institute Logo
Van Andel Institute

VARi has several research programs in basic sciences that will improve our understanding of the cancer process, including programs rich in functional genomics. They have a long-term commitment to the development of programs that facilitate the translation of these basic science discoveries into therapeutic strategies for attacking cancer and thus improving human health.

Harvard Bioscience Logo
Harvard Bioscience

Harvard Bioscience acquires and distributes laboratory equipment and products for companies and institutions in the life sciences field.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.